BlackRock’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-3,736,334
| Closed | -$19.3M | – | 5175 |
|
|
2019
Q2 | $19.3M | Buy |
3,736,334
+213,530
| +6% | +$960K | ﹤0.01% | 2861 |
|
|
2019
Q1 | $12.7M | Sell |
3,522,804
-106,791
| -3% | -$463K | ﹤0.01% | 2993 |
|
|
2018
Q4 | $22.2M | Buy |
3,629,595
+190,011
| +6% | +$1.16M | ﹤0.01% | 2674 |
|
|
2018
Q3 | $20.1M | Buy |
3,439,584
+91,344
| +3% | +$456K | ﹤0.01% | 2870 |
|
|
2018
Q2 | $14.2M | Buy |
3,348,240
+345,204
| +11% | +$1.74M | ﹤0.01% | 3056 |
|
|
2018
Q1 | $13.2M | Sell |
3,003,036
-61,079
| -2% | -$273K | ﹤0.01% | 2981 |
|
|
2017
Q4 | $16.1M | Sell |
3,064,115
-49,754
| -2% | -$304K | ﹤0.01% | 2891 |
|
|
2017
Q3 | $19.1M | Buy |
3,113,869
+118,579
| +4% | +$750K | ﹤0.01% | 2832 |
|
|
2017
Q2 | $21.7M | Buy |
2,995,290
+346,189
| +13% | +$2.13M | ﹤0.01% | 2748 |
|
|
2017
Q1 | $14M | Buy |
2,649,101
+2,645,880
| +82,145% | +$17.9M | ﹤0.01% | 2958 |
|
|
2016
Q4 | $23K | Sell |
3,221
-558
| -15% | -$4.51K | ﹤0.01% | 3220 |
|
|
2016
Q3 | $35K | Buy |
3,779
+469
| +14% | +$3.9K | ﹤0.01% | 3120 |
|
|
2016
Q2 | $21K | Buy |
3,310
+1,470
| +80% | +$9.45K | ﹤0.01% | 3258 |
|
|
2016
Q1 | $11K | Buy |
1,840
+1,194
| +185% | +$4.49K | ﹤0.01% | 3134 |
|
|
2015
Q4 | $4K | Hold |
646
| – | – | ﹤0.01% | 3221 |
|
|
2015
Q3 | $5K | Hold |
646
| – | – | ﹤0.01% | 3040 |
|
|
2015
Q2 | $10K | Sell |
646
-116
| -15% | -$1.68K | ﹤0.01% | 2818 |
|
|
2015
Q1 | $12K | Hold |
762
| – | – | ﹤0.01% | 2652 |
|
|
2014
Q4 | $14K | Hold |
762
| – | – | ﹤0.01% | 2572 |
|
|
2014
Q3 | $8K | Buy |
762
+158
| +26% | +$1.92K | ﹤0.01% | 2886 |
|
|
2014
Q2 | $9K | Buy |
+604
| New | +$8.56K | ﹤0.01% | 2877 |
|
Other funds holding PETX
BlackRock's PETX Position: Q3 2019 in Review
BlackRock sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 3,736,334 shares — an estimated $19.3M sold.
BlackRock first reported a position in PETX in Q2 2014 and held it in 21 quarters. The position peaked at $22.2M in Q4 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- BlackRock reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- BlackRock sold 3,736,334 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $19.3M.
- BlackRock first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 21 quarters.
- BlackRock's Aratana Therapeutics, Inc. position peaked at $22.2M in Q4 2018.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on BlackRock's 13F filing for Q3 2019, filed 8 Nov 2019.